# Treatment of Non-severe Covid-19 Outpatients With Xagrotin, Phase 3

> **NCT05222425** · PHASE3 · UNKNOWN · sponsor: **Biomad AS** · enrollment: 3000 (estimated)

## Conditions studied

- Sars-cov-2

## Interventions

- **DRUG:** Xagrotin
- **DRUG:** Green tea

## Key facts

- **NCT ID:** NCT05222425
- **Lead sponsor:** Biomad AS
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2022-06-01
- **Primary completion:** 2022-10-15
- **Final completion:** 2022-12-07
- **Target enrollment:** 3000 (ESTIMATED)
- **Last updated:** 2022-03-17


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05222425

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05222425, "Treatment of Non-severe Covid-19 Outpatients With Xagrotin, Phase 3". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT05222425. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*